Difference between revisions of "Fibrillin-1"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| align="center" colspan="2" bgcolor="#ffffff" | | | align="center" colspan="2" bgcolor="#ffffff" | | ||
| Line 50: | Line 50: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:36, 10 March 2015
| Fibrillin-1 | |
|---|---|
| Substrate peptide name | Fibrillin-1 |
| Synonyms | FBN |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular matrix
Plasma |
| Swissprot ID | P35555 |
| Reactive glutamines | Q3 |
| Reactive lysines | K7 |
| Substrate sequence | EDGFFKI
APQQEA |
| Structure | 1EMN |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:20223517 |
| Notes | |
